Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis

Clinical Rheumatology

Volumn 19, Issue 6, 2000, Pages 442-444

  Biasi, D ^a   Caramaschi, P ^a   Carletto, A ^a   Bambara, L M ^a  

^a POLICLINICO BORGO ROMA   (Italy)

Author keywords

Fludarabine; Refractory rheumatoid arthritis

Indexed keywords

FLUDARABINE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PREDNISONE; TREATMENT FAILURE; VIDARABINE;

EID: 0034514155     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670070002     Document Type: Article

References (17)

1. Soluble tumor necrosis factor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis
2. A multi-centre, double-blind randomized trial of low-dose cyclosporine and placebo therapy in combination with methotrexate in patients with severe rheumatoid arthritis
3. Combination therapy with cyclosporin in rheumatoid arthritis
4. Treatment of refractory rheumatoid arthritis with low-dose cyclophosphamide. Long-term follow-up of 108 patients
5. CAMPATH-1H, a humanized antilymphocyte monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study
6. An open study of pentoxifylline in the treatment of severe rheumatoid arthritis
7. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia
8. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia
9. Phase II trial of fludarabine phosphate in lymphoma. An effective new agent in low grade lymphomas
10. Response assessment in chronic lymphocytic leukemia after fludarabine plus prechnisone: Clinical, pathologic, immunophenotypic, and molecular analysis
11. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine
12. The pharmacodynamics of fludarabine in rheumatoid arthritis
13. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
14. Joint destruction in rheumatoid arthritis: Biological bases
15. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis
16. A pilot study: Use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures
17. The immunopathogenesis of rheumatoid arthritis